Drug Profile


Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Columbia University; Dana-Farber Cancer Institute; Regenacy Pharmaceuticals
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Breast cancer; Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 03 Dec 2016 Acetylon completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT01323751)
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in non-Hodgkin's lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 02 Aug 2016 The National Cancer Institute and Mayo Clinic plan a phase Ib trial for Cholangiocarcinoma (Inoperable/Unresectable, Metastatic disease, Combination therapy) in USA (PO) (NCT02856568)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top